肿瘤药学
腫瘤藥學
종류약학
ANTI-TUMOR PHARMACY
2013年
4期
259-263
,共5页
何志坚%钟睿%刘海云%敖帆
何誌堅%鐘睿%劉海雲%敖帆
하지견%종예%류해운%오범
药物敏感性试验%ATP- 生物荧光法%鼻咽癌%新辅助化疗
藥物敏感性試驗%ATP- 生物熒光法%鼻嚥癌%新輔助化療
약물민감성시험%ATP- 생물형광법%비인암%신보조화료
Tumor chemosensitivity essay%ATP-TCA assay%Nasopharyngeal carcinoma%Neoadjuvant chemotherapy
目的探讨肿瘤体外药敏实验 ATP 生物荧光法(ATP-TCA)在筛选鼻咽癌新辅助化疗药物中的应用。方法应用 ATP-TCA 法体外检测84例鼻咽癌活检组织对8种常用化疗药物的敏感性。结果组织标本的可评估率为100.0%。PXT 最敏感,体外有效率为50.00%,其次为 DDP (35.45%)、5-Fu (31.25%)、NVB(23.53%)、HCT (10.53%)、MTX(10.53%)、VP-16(7.69%)、THP(5.00%)。化疗药物对鼻咽癌的杀伤作用具有较强的个体差异性。结论体外鼻咽癌组织对8种化疗药物敏感性不同,存在明显差异性, ATP 生物荧光肿瘤体外药物敏感性检测法可用于临床制定个体化的鼻咽癌新辅助化疗方案。
目的探討腫瘤體外藥敏實驗 ATP 生物熒光法(ATP-TCA)在篩選鼻嚥癌新輔助化療藥物中的應用。方法應用 ATP-TCA 法體外檢測84例鼻嚥癌活檢組織對8種常用化療藥物的敏感性。結果組織標本的可評估率為100.0%。PXT 最敏感,體外有效率為50.00%,其次為 DDP (35.45%)、5-Fu (31.25%)、NVB(23.53%)、HCT (10.53%)、MTX(10.53%)、VP-16(7.69%)、THP(5.00%)。化療藥物對鼻嚥癌的殺傷作用具有較彊的箇體差異性。結論體外鼻嚥癌組織對8種化療藥物敏感性不同,存在明顯差異性, ATP 生物熒光腫瘤體外藥物敏感性檢測法可用于臨床製定箇體化的鼻嚥癌新輔助化療方案。
목적탐토종류체외약민실험 ATP 생물형광법(ATP-TCA)재사선비인암신보조화료약물중적응용。방법응용 ATP-TCA 법체외검측84례비인암활검조직대8충상용화료약물적민감성。결과조직표본적가평고솔위100.0%。PXT 최민감,체외유효솔위50.00%,기차위 DDP (35.45%)、5-Fu (31.25%)、NVB(23.53%)、HCT (10.53%)、MTX(10.53%)、VP-16(7.69%)、THP(5.00%)。화료약물대비인암적살상작용구유교강적개체차이성。결론체외비인암조직대8충화료약물민감성불동,존재명현차이성, ATP 생물형광종류체외약물민감성검측법가용우림상제정개체화적비인암신보조화료방안。
Objective To investigate the drug sensitivity of nasopharyngeal carcinoma in vitro by ATP-TCA, and provide basis of neoadjuvant chemotherrap in nasopharyngeal carcinoma. Methods ATP-TCA was applied to determine the drug sensi-tivity of 84 nasopharyngeal carcinomas to eight common chemotherapeutics. Results The rate of evaluation of tissue samples was 100%. The drug with most sensitive efficiency was PXT (50%), followed by DDP (35.45%), 5-Fu (31.25%), NVB (23.53%), HCT (10.53%), MTX (10.53%), VP-16 (7.69%), THP (5.00%). The chemotherapy drugs showed strong individual difference in the killing effect on nasopharyngeal carcinoma. Conclusions The nasopharyngeal carcinoma tissues in vitro had significantly different sensitivity to eight kinds of chemotherapy drugs. ATP bioluminescence tumor drug sensitivity assay can be used in the clinical setting of individualized neoadjuvant chemotherapy for nasopharyngeal carcinoma (NPC) patients.